Cargando…

Fee-for-value in the pharmaceutical industry: a policy framework applying data science to negotiate drug prices

Detalles Bibliográficos
Autor principal:	Patel, Nisarg A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2017
Materias:	New Developments
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5570706/ https://www.ncbi.nlm.nih.gov/pubmed/28852564 http://dx.doi.org/10.1093/jlb/lsx002

Ejemplares similares

Off-patent drugs at brand-name prices: a puzzle for policymakers
por: Tallapragada, Naren P.
Publicado: (2016)

New science, old convictions − Texas Senate Bill 344: identifying further necessary reform in forensic science
por: Soni, Naina
Publicado: (2015)

Concussions and youth football: using a public health law framework to head off a potential public health crisis
por: Baugh, Christine M., et al.
Publicado: (2015)

Cook v. FDA and the importation and release of lethal injection drugs
por: Meyers, Nicholas
Publicado: (2014)

Executive action to combat the rise of drug-resistant bacteria: is agricultural antibiotic use sufficiently addressed?
por: Jooma, Sonya
Publicado: (2015)

Negotiating prices of drugs for rare diseases
por: Henrard, Séverine, et al.
Publicado: (2016)

Predictors of negotiated prices for new drugs in Germany
por: Gandjour, Afschin, et al.
Publicado: (2020)

Pharmaceutical pricing and reimbursement policies: perspectives for the future
por: Gray, Andrew L
Publicado: (2015)

Challenges and opportunities for pharmaceutical pricing and reimbursement policies
por: Vogler, Sabine, et al.
Publicado: (2015)

The FDA and genetic testing: improper tools for a difficult problem
por: Willmarth, Kirk
Publicado: (2015)

The case for pain neuroimaging in the courtroom: lessons from deception detection
por: Salmanowitz, Natalie
Publicado: (2015)

Patenting nature or protecting culture? Ethnopharmacology and indigenous intellectual property rights
por: McGonigle, Ian Vincent
Publicado: (2016)

Recently proposed changes to legal and ethical guidelines governing human subjects research
por: Largent, Emily A.
Publicado: (2016)

Inherited proclivity: When should neurogenetics mitigate moral culpability for purposes of sentencing?
por: Segal, J Bradley
Publicado: (2016)

What's in a name: the Vermont Genetically Engineered Food Labeling Act
por: McPherson, Malia J.
Publicado: (2014)

Newborn screening in the genomics era
por: Rego, Shannon
Publicado: (2014)

Incidental findings and future testing methodologies: potential application of the ACMG 2013 recommendations
por: Richardson, Anastasia
Publicado: (2014)

Gene patents at the Supreme Court: Association for Molecular Pathology v. Myriad Genetics
por: Bakshi, Ashish M.
Publicado: (2014)

FDA regulation of clinical decision support software
por: Karnik, Komal
Publicado: (2014)

State-level legislation on follow-on biologic substitution
por: Benedict, Adriana Lee
Publicado: (2014)

Forward, Gillick: Are competent children autonomous medical decision makers? New developments in Australia
por: Lennings, Nicholas J.
Publicado: (2015)

Genetic citizenship: DNA testing and the Israeli Law of Return
por: McGonigle, Ian V., et al.
Publicado: (2015)

Amnesia and criminal responsibility
por: Go, Gawon
Publicado: (2017)

The testosterone rule—constructing fairness in professional sport
por: Sudai, Maayan
Publicado: (2017)

Mitochondrial replacement therapy: the UK and US regulatory landscapes
por: Castro, Rosa J.
Publicado: (2016)

Strange bedfellows: anti-abortion and disability rights advocacy
por: Giric, Stefanija
Publicado: (2016)

Definitions of death: brain death and what matters in a person
por: Sarbey, Ben
Publicado: (2016)

Designing a standard of proof: the case for professional standards in next-generation sequencing laboratory-developed tests
por: Walker, Quinn
Publicado: (2017)

Measles, misinformation, and risk: personal belief exemptions and the MMR vaccine
por: Bowes, Johnathan
Publicado: (2016)

Midwives as drivers of reproductive health commodity security in Kaduna State, Nigeria
por: Alayande, Audu, et al.
Publicado: (2016)

Negotiating with Backbone: Eight Sales Strategies to Defend Your Price and Value
por: Holden, Reed
Publicado: (2012)

Negotiating with Backbone: Eight Sales Strategies to Defend Your Price and Value
por: Holden, Reed
Publicado: (2015)

The price of innovation - the role of drug pricing in financing pharmaceutical innovation. A conceptual framework
por: Moreno, Santiago G., et al.
Publicado: (2019)

Payer-Negotiated Prices for Telemedicine Services
por: Wu, Shannon S., et al.
Publicado: (2022)

The impact of alternative pricing methods for drugs in California Workers’ Compensation System: Fee-schedule pricing
por: Wilson, Leslie, et al.
Publicado: (2018)

Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
por: Docteur, Elizabeth, et al.
Publicado: (2015)

Health technology assessment-informed pricing negotiation in China: higher negotiated price for more effective targeted anticancer medicines?
por: Huang, Cong, et al.
Publicado: (2022)

Applying an authentic partnership approach to facilitate optimal health of Aboriginal children
por: Sprigg dos Santos, Naomi, et al.
Publicado: (2022)

Prices and Clinical Benefit of National Price-Negotiated Anticancer Medicines in China
por: Zhang, Yichen, et al.
Publicado: (2022)

The H3Africa policy framework: negotiating fairness in genomics
por: de Vries, Jantina, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_605phgc0blu8r6mbvu4e5qurbs